{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.15","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54","upperLimit":"64","value":"59"},{"groupId":"OG001","lowerLimit":"48","upperLimit":"59","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"description":"Percentage of participants who achieved a complete response (CR). A CR was defined as normalization of blood counts and a marrow showing less than 5% blasts occurring on or before day 60.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will receive daunorubicin 60 mg/m\\^2 by IV push days 1-3 plus cytarabine 200 mg/m\\^2 IV days 1-7, and midostaurin 50 mg orally twice daily days 8-21. Participants achieving remission will receive four 28 day cycles of high dose cytarabine (3000 mg/m\\^2) days 1, 3, \\& 5 and midostaurin at 50 mg orally twice daily days 8-14. Maintenance therapy was given to participants who continued in remission for 12 28-day cycles of midostaurin 50 mg orally twice daily.","id":"OG000","title":"Induction and Consolidation Chemotherapy Plus Midostaurin"},{"description":"Patients will receive daunorubicin 60 mg/m\\^2 by IV push days 1-3 plus cytarabine 200 mg/m\\^2 IV days 1-7, and placebo 50 mg orally twice daily days 8-21. Participants achieving remission will receive four 28 day cycles of high dose cytarabine (3000 mg/m\\^2) days 1, 3, \\& 5 and placebo at 50 mg orally twice daily days 8-14. Maintenance therapy was given to participants who continued in remission for 12 28-day cycles of placebo 50 mg orally twice daily.","id":"OG001","title":"Induction and Consolidation Chemotherapy Plus Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Induction therapy (up to 60 days)","title":"Complete Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}